Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center
Authors:
Open Access
- 1 April 2016
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 11 (5) , 3501-3507
Abstract
Peritoneal carcinomatosis (PC) of gastric origin is currently recognized as a terminal disease with a poor prognosis. Advancements in novel therapeutic approaches, including intraperitoneal chemotherapy (IPC), have recently been made and it is believed that this may have contributed to the improved survival observed in patients with PC. The present study aimed to investigate overall survival (OS) and the associated prognostic factors in patients with PC of gastric origin who underwent IPC. A total of 57 patients were studied, with a median age of 51 years. The median follow-up time was 12.4 months. PC was diagnosed in all patients with gastric cancer. The median survival time of all patients was 10.1 months, whilst the OS rate at 1, 2 and 3 years was observed to be 46, 19 and 12%, respectively. Symptomatic ascites and a signet ring cell (SRC) histopathological type were demonstrated to signify a poor prognosis. Complete resection of all gross disease (CCR-0) and an increased number of cycles of systemic chemotherapy were independent factors that were observed to correlate with increased OS. The most common morbidities of grade 3/4 adverse effects were bone marrow suppression, nausea or vomiting, and diarrhea. In conclusion, IPC is an important treatment option for patients with PC that has originated from gastric cancer. Symptomatic ascites and SRC adenocarcinoma serve as negative clinicopathological prognostic factors, whilst CCR-0 and increased systemic chemotherapy cycles (≥4 cycles) may prove to be an important therapeutic option for PC patients.Keywords
This publication has 33 references indexed in Scilit:
- Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case–control studyAnnals of Oncology, 2011
- Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.European Journal of Surgical Oncology, 2011
- Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Hyperthermic Intraperitoneal Chemotherapy Using a Closed Abdominal ProcedureThe Journal of Clinical Pharmacology, 2011
- Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapyCancer, 2010
- Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese centerJournal of Surgical Oncology, 2010
- A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal OriginAnnals of Surgical Oncology, 2009
- Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal CarcinomaJournal of Clinical Oncology, 2006
- Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancerBritish Journal of Cancer, 2006
- Immunohistochemical Characterization of Signet-Ring Cell Carcinomas of the Stomach, Breast, and ColonAmerican Journal of Clinical Pathology, 2004
- Intraoperative Chemohyperthermia in the Management of Digestive CancersOncology, 1993